GlassScriptPhysician profile
Vladimir Diaz
NPI 1831307123
$1,175.20
in general payments reported to CMS, 2019-2025
13 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.99 · 2020: $30.45 · 2021: $187 · 2022: $166 · 2023: $54.97 · 2024: $270 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.52 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $264.81 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $184.94 | 2023-2025 | Farxiga |
| Amgen INC. | $110.14 | 2022-2025 | Repatha, Repatha, Evenity |
| Insulet Corporation | $59.68 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.62 | 2022 | |
| Sumitomo Pharma America, INC. | $48.79 | 2025 | Gemtesa |
| Averitas Pharma INC. | $35.79 | 2024 | Qutenza |
| Dexcom, INC. | $35.41 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $29.15 | 2024 | |
| Pfizer INC. | $27.06 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.59 | 2024 | Voquezna |
| Catalyst Pharmaceuticals, INC. | $17.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.